The science behind 25 years of ovarian stimulation for in vitro fertilization.
about
FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniquesFSH replaced by low-dose hCG in the late follicular phase versus FSH alone for assisted reproductive techniquesComprehensive Review on Kisspeptin and Its Role in Reproductive DisordersOvarian hyperstimulation syndrome: pathophysiology, staging, prediction and preventionOvarian germline stem cells: an unlimited source of oocytes?Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysisMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization.CLARITY reveals dynamics of ovarian follicular architecture and vasculature in three-dimensions.Is there a recommended maximum starting dose of FSH in IVF?Research resource: interactome of human embryo implantation: identification of gene expression pathways, regulation, and integrated regulatory networks.Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment.MicroRNAs miR-30b, miR-30d, and miR-494 regulate human endometrial receptivity.WEE2 is an oocyte-specific meiosis inhibitor in rhesus macaque monkeys.Comparative pharmacology of a new recombinant FSH expressed by a human cell line.Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.Physiology and Endocrinology of the Ovarian Cycle in Macaques.Mild ovarian stimulation for IVF: 10 years later.Associations between Individual and Combined Polymorphisms of the TNF and VEGF Genes and the Embryo Implantation Rate in Patients Undergoing In Vitro Fertilization (IVF) ProgramsFollicular steroid hormones as markers of oocyte quality and oocyte development potential.Intraovarian control of early folliculogenesisImpact of exogenous gonadotropin stimulation on circulatory and follicular fluid cytokine profilesIndividualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients.Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study.Study of two strategies to induce follicular wave emergence for assisted reproductive treatments (ART)-a preliminary trial.External validation and calibration of IVFpredict: a national prospective cohort study of 130,960 in vitro fertilisation cycles.Will imatinib compromise reproductive capacity?Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles.A case report: successful pregnancy after controlled ovarian hyperstimulation by using short-acting gonadotropin releasing hormone agonist only.Cut-Off Levels of Anti-Mullerian Hormone for The Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome.Paeonia lactiflora Enhances the Adhesion of Trophoblast to the Endometrium via Induction of Leukemia Inhibitory Factor Expression.Maternal control of early embryogenesis in mammalsMapping the follicle-stimulating hormone-induced signaling networks.Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.Characterization of the Transcriptional Complexity of the Receptive and Pre-receptive Endometria of Dairy GoatsA novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.Why more is less and less is more when it comes to ovarian stimulation.MILD ovarian stimulation with GnRH-antagonist vs. long protocol with low dose FSH for non-PCO high responders undergoing IVF: a prospective, randomized study including thawing cycles.Does Unilateral Oocyte Retrieval due to Transvaginally Inaccessible Ovaries, Contrary to Common Beliefs, Affect IVF/ICSI Treatment Outcomes That Much?Characterisation of Population Pharmacokinetics and Endogenous Follicle-Stimulating Hormone (FSH) Levels After Multiple Dosing of a Recombinant Human FSH (FE 999049) in Healthy WomenPopulation Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending Doses
P2860
Q24199010-22AB8D36-6598-4F0E-87F7-AE710636A65EQ24201872-F6D36059-1558-4104-A6A3-0BAC25FFC558Q26801682-684FF4A4-1826-4758-9D63-C75300E7B6F0Q26827593-8B396FA6-D489-44F5-B76F-D00EDE4CD902Q27023685-C739C2FD-1C1E-453F-8E49-F8042C27CCDCQ28293370-BF6A423F-21E9-4B33-9E13-41E8D2D497A9Q30399747-9AFA106F-7FF6-4A6F-BEBA-9A1A28552FDAQ30842751-28861785-4611-47B2-BDD4-D4AAAF8D9A69Q33287991-A6110353-72F1-4530-ACFC-636F31721230Q33636729-AF3D6B10-E532-4A19-9434-4BFDE240733BQ33734705-AB4854AF-B236-4A75-A890-E9AB7CCBFE7CQ33829568-3DF9A283-B32B-4197-A726-ED77AFE11988Q33868857-55AB9EC2-3163-4F3D-94DC-D8EEEECDF26CQ33904231-FF874284-B138-462D-981D-F8A07B0EBC06Q33944146-84883633-F526-4ED1-BE03-407912154486Q34129260-35E7B210-45C3-4319-89A8-14B71A2C16D6Q34139320-BCFB3BF9-17C0-4BD7-834F-788AF5623E17Q34232658-5B455B15-C9D1-4B46-81FA-D260F3FCFADDQ34500293-1469ABEC-D5E6-4B6C-BBF4-80A39E3BE8E2Q35024088-70D8CA34-08EB-46B3-B6B6-67F668E651E9Q35100094-C90F9C77-5923-4AE9-A5B6-298A9F4FB731Q35147438-197254FC-F3F4-4180-8CB9-CA35E510A09DQ35186866-996BA11F-4E82-454C-A2D0-780F384B714EQ35236614-23928C6F-C586-4619-94DB-5099788484C2Q35324848-26083C55-2BDA-41FE-85C0-8FF975B86295Q35584349-94CEB801-6780-4833-BE5B-A7E2355C4278Q35621462-F468181B-4A30-4D31-87AF-3546A5A1B0C9Q35845572-51257718-F274-4E9B-9AFE-5B48343E5704Q35898934-D2C2B471-42BE-46FA-A53A-41C04114EB82Q35912947-0A3333C7-0ACE-4823-A81D-B7136332EE46Q35984494-CCF0CA49-9D06-40BA-85FA-4F359D42754AQ35999305-050D91CD-0273-4389-A05D-4A026930BDE3Q36060453-A574FE14-95A0-4D8B-84D5-A185609DDA7CQ36064457-AA6DF971-3515-45FD-A01A-F6D7030FA8FBQ36159645-0279A5B7-1133-49D0-854C-4EE68CDAC628Q36378491-5B20A1E1-9EB2-4DDC-AF7F-6DA16B1C302AQ36484629-56B2BC3B-AD55-4B44-9CFC-024324AE8149Q36792690-3E72188B-7E27-40FD-A0B7-D6ACF341B902Q36923996-483EB754-D835-4A75-8CD5-D37F5EF86F05Q36924006-693C612B-6F96-4422-A1EB-6FA67FD89639
P2860
The science behind 25 years of ovarian stimulation for in vitro fertilization.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The science behind 25 years of ovarian stimulation for in vitro fertilization.
@ast
The science behind 25 years of ovarian stimulation for in vitro fertilization.
@en
type
label
The science behind 25 years of ovarian stimulation for in vitro fertilization.
@ast
The science behind 25 years of ovarian stimulation for in vitro fertilization.
@en
prefLabel
The science behind 25 years of ovarian stimulation for in vitro fertilization.
@ast
The science behind 25 years of ovarian stimulation for in vitro fertilization.
@en
P2093
P356
P1433
P1476
The science behind 25 years of ovarian stimulation for in vitro fertilization.
@en
P2093
Bart C J M Fauser
Linda C Giudice
Nick S Macklon
Richard L Stouffer
P304
P356
10.1210/ER.2005-0015
P577
2006-01-24T00:00:00Z